iBio (IBIO) Aandeel Koers

iBio Inc, trading under the ticker symbol IBIO and identified by ISIN US4510337086, is a biotechnology enterprise headquartered in New York City, United States. Operating within the health care sector, specifically in the biotechnology industry, the company has maintained a relatively small operational footprint, with reported employee counts varying between twenty and seven full-time staff members depending on the source of data. iBio went public on August 18, 2008, establishing its presence in the financial markets as a developer and manufacturer of biotherapeutics. The firm’s strategic focus lies in the commercialization of its proprietary technologies and product candidates, alongside the provision of product development and manufacturing services to external clients and collaborators. Central to its business model is the utilization of a transformative platform designed for the development and production of biologics using hydroponically grown green plants. This approach leverages plant-based protein expression technologies, which are applied to the creation of vaccines and therapeutic proteins. The company’s technological portfolio includes specific innovations such as iBioLaunch technology and iBioModulator, which facilitate efficient production processes. These technologies are versatile and applicable to a broad range of product candidates. The firm is actively engaged in developing and commercializing select biopharmaceutical products, with a particular emphasis on treatments for fibrotic diseases. Additionally, iBio’s platform supports the production of enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are traditionally derived from human blood plasma. By shifting production methods away from traditional biological systems, the company aims to offer scalable and cost-effective solutions for the generation of complex therapeutic proteins. The company’s website, https://www.ibioinc.com/, serves as a primary resource for further information regarding its ongoing research, development initiatives, and commercial partnerships. Despite its modest size, iBio Inc positions itself as a specialized player in the biotechnology landscape, focusing on niche applications of plant-based biomanufacturing to address unmet medical needs in areas such as fibrosis and infectious disease prevention through vaccine development. The integration of its proprietary technologies into its operational framework underscores its commitment to advancing the field of biotherapeutics through innovative manufacturing methodologies.